Brief: Maxcyte And Allogene Therapeutics Sign Clinical And Commercial License Agreement To Enable The Advancement Of Allogeneic Car T (Allocar T™) Therapies
24/03/2020 12:37
March 24 (Reuters) - Allogene Therapeutics Inc ALLO.O :
* MAXCYTE AND ALLOGENE THERAPEUTICS SIGN CLINICAL AND
COMMERCIAL
LICENSE AGREEMENT TO ENABLE THE ADVANCEMENT OF ALLOGENEIC CAR T
(ALLOCAR T™) THERAPIES
* ALLOGENE THERAPEUTICS - AGREEMENT ENABLES ALLOGENE TO
UTILIZE
MAXCYTE'S EXPERT PLATFORM IN TARGET CANDIDATES
* ALLOGENE THERAPEUTICS INC - UNDER TERMS, MAXCYTE TO GET
UNDISCLOSED DEVELOPMENT, APPROVAL & COMMERCIAL MILESTONES IN
ADDITION TO OTHER LICENSING FEES
Source text for Eikon: ID:nPnglMYWa
Further company coverage: ALLO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on MaxCyte
See all newsMaxCyte, Inc. MaxCyte, Inc. - MXCR - Second Price Monitoring Extn
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Price Monitoring Extension
Brief: Maxcyte And Allogene Therapeutics Sign Clinical And Commercial License Agreement To Enable The Advancement Of Allogeneic Car T (Allocar T™) Therapies
Brief: Maxcyte Signs Agreement With KSQ Therapeutics
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Agreement with KSQ Therapeutics